Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Monday

Myriad Genetics (NASDAQ:MYGN) is anticipated to issue its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect Myriad Genetics to post earnings of ($0.02) per share and revenue of $207.5650 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:30 PM ET.

Myriad Genetics Trading Down 2.1%

MYGN opened at $4.29 on Friday. Myriad Genetics has a 1-year low of $3.76 and a 1-year high of $15.18. The stock has a market capitalization of $399.87 million, a PE ratio of -0.99 and a beta of 1.90. The company has a current ratio of 2.33, a quick ratio of 2.12 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $5.83 and a two-hundred day moving average price of $6.63.

Hedge Funds Weigh In On Myriad Genetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC bought a new position in shares of Myriad Genetics during the 3rd quarter valued at about $106,000. State of Wyoming raised its holdings in Myriad Genetics by 256.1% during the 2nd quarter. State of Wyoming now owns 30,772 shares of the company’s stock worth $163,000 after buying an additional 22,131 shares during the period. Cerity Partners LLC bought a new position in Myriad Genetics in the second quarter valued at approximately $119,000. Baird Financial Group Inc. boosted its holdings in shares of Myriad Genetics by 144.7% in the second quarter. Baird Financial Group Inc. now owns 29,059 shares of the company’s stock valued at $154,000 after buying an additional 17,186 shares during the period. Finally, Nebula Research & Development LLC acquired a new position in shares of Myriad Genetics in the second quarter valued at approximately $79,000. Institutional investors own 99.02% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MYGN. Wells Fargo & Company boosted their price objective on shares of Myriad Genetics from $6.00 to $6.50 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Zacks Research cut Myriad Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Myriad Genetics in a research report on Monday, December 29th. TD Cowen reiterated a “hold” rating on shares of Myriad Genetics in a report on Tuesday, November 4th. Finally, UBS Group lifted their price objective on Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.44.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.